SQZ Biotechnologies Co (SQZB)

[crudeoil24]

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases, and other serious conditions. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. It has three oncology candidates in clinical trials across its SQZ Antigen Presenting Cell (APC), SQZ enhanced APC (eAPC) and SQZ Activating Antigen Carrier (AAC), cell therapy platforms. In its autoimmune diseases portfolio, the Company is developing its SQZ Tolerizing Antigen Carrier (TAC), cell therapy platform to restore immune tolerance to self-antigens or other autoimmune disease-associated antigens that are central to disease pathogenesis. APC platform is focused on generating CD8+ T cell responses. SQZAPCs are created by ex vivo engineering of a patient's own peripheral blood mononuclear cells.